Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Durvalumab + FANG vaccine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|FANG vaccine||Vigil|bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine||Vigil (FANG vaccine) is a combination of autologous tumor cells expressing recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and RNAi against furin convertase. FANG stimulates cell maturation through GM-CSF and prevents GM-CSF degradation by Tgfb1 and Tgfb2 (PMID: 22186789).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02725489||Phase II||Durvalumab + FANG vaccine||Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers||Active, not recruiting|